Phio Pharmaceuticals
PHIO
11 hedge funds and large institutions have $798K invested in Phio Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
263% more capital invested
Capital invested by funds: $220K → $798K (+$579K)
83% more funds holding
Funds holding: 6 → 11 (+5)
1.64% more ownership
Funds ownership: 0.38% → 2.02% (+1.6%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$612K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$91.7K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$88.1K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$55K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$41.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$11.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $450K | +$612K | +17,417 | New |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $70K | +$55K | +1,567 | +137% |
|
|
BCM
3
Bridgeway Capital Management
Houston,
Texas
| $67.4K | +$91.7K | +2,610 | New |
|
|
AFM
4
Anson Funds Management
Dallas,
Texas
| $64.8K | +$88.1K | +2,508 | New |
|
5
Cambridge Investment Research Advisors
Fairfield,
Iowa
| $41K | – | – | – |
|
6
Bank of Montreal
Toronto,
Ontario, Canada
| $38.5K | +$39K | +1,111 | New |
|
|
7
Renaissance Technologies
New York
| $32K | -$11.7K | -334 | -21% |
|
|
8
Cetera Investment Advisers
Schaumburg,
Illinois
| $30.6K | +$41.6K | +1,185 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $3.8K | +$5.16K | +147 | New |
|
10
Morgan Stanley
New York
| $359 | – | – | – |
|
11
Wells Fargo
San Francisco,
California
| $32 | – | – | – |
|
12
JP Morgan Chase
New York
| $11 | – | – | – |
|
13
BlackRock
New York
| $3 | – | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$1.16K | -23 | Closed |
|
PHIO Hedge Fund Activity: Q2 2023 in Review
11 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2023, worth a combined $798K — up 263% from $220K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PHIO positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $612K. The largest seller was Renaissance Technologies, cutting an estimated $11.7K.
- 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2023, up from 6 in Q1 2023.
- Funds reported $798K of Phio Pharmaceuticals stock for Q2 2023, up 263% quarter-over-quarter.
- 6 funds opened new Phio Pharmaceuticals positions in Q2 2023 and 1 closed out, a net change of +5 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2023 was Sabby Management, an estimated $612K added.
- The largest Phio Pharmaceuticals seller in Q2 2023 was Renaissance Technologies, an estimated $11.7K sold.
Based on aggregated 13F filings for Q2 2023.